Fact CheckerSign in

NCT07161258RecruitingPhase 2

A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS)

An Open-label, Single-arm Study to Evaluate Pharmacokinetics, Pharmacodynamic Effects, Safety and Tolerability of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis

Source: ClinicalTrials.gov · Last updated 13 Oct 2026

Brief summary (registry, in English)

This open label, single arm study will evaluate the PK and PD effects of fenebrutinib in children and adolescents with RMS aged between 10 and \< 18 years. This study consists of a Dose Exploration Period and an Optional Extension Period. Eligible participants may choose to continue treatment with fenebrutinib in the optional extension period after completing the dose exploration period.

Status (registry)
Recruiting
Phase (registry)
Phase 2
Study type
Interventional
Enrollment
12 (estimated)
First submitted
20 Aug 2025
Start date
6 Oct 2025
Primary completion date
8 Jun 2027
Lead sponsor
Hoffmann-La Roche
NCT number
NCT07161258
EU CT number
2024-519800-28-00

What you commit to

  • Study type: Interventional · Phase 2
  • Planned participants: 12
  • From 6 Oct 2025 to the primary completion date, 8 Jun 2027
  • 17 sites in 7 countries
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Recent or anticipated use of prohibited medications/treatments:
  • Drugs interacting with fenebrutinib (Cytochrome P450 3A4 \[CYP3A4\] inhibitors)
  • Any other investigational therapy, anticoagulants, certain vaccines

Other illness

  • Co-morbid Conditions:
  • Potentially confounding neurological, somatic, or metabolic disorders
  • Current clinically significant psychiatric or medical illness
  • History of cancer, transplants, or bleeding disorders
  • Active, recurrent, or chronic infections
  • Certain disease-modifying therapy (DMT) and other immunosuppressants

Lab values

  • Abnormal liver function tests or blood counts

Other

  • A diagnosis of primary progressive multiple sclerosis (PPMS) or non-active secondary progressive multiple sclerosis (SPMS)
  • Inability to complete an MRI scan or get gadolinium
  • Sensitivity or intolerance to any ingredient (including excipients) of fenebrutinib tablets
  • A score of 4 or 5 on the "last 6 months" section of the screening SI section or "yes" on any item of the "last 6 months" Suicidal Behavior (SB) section of the C-SSRS or a positive answer on Question 9 of the Patient Health Questionnaire-9 Modified for Adolecents (PHQ-A) or significant risk of suicide, in the investigator's judgment

Who the study is looking for

  • A diagnosis of RMS in accordance with the International Pediatric Multiple Sclerosis Study Group (IPMSSG) criteria for pediatric MS, Version 2012, and the revised 2017 McDonald Criteria and one or more of the following: at least one MS relapse during the previous year or two MS relapses in the previous 2 years or evidence of at least one Gd enhancing lesion on MRI within 6 month
  • Expanded Disability Status Scale (EDSS) at screening from 0 to 5.5 points, inclusive
  • Children and adolescents must have received all childhood vaccinations as per local/national recommendations for childhood vaccination against infectious diseases

Age in the registry: 10 years to 17 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (17)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
INECO Neurociencias Oroño
Coordinator of this site? Confirm its status
RosarioArgentinaRecruiting
Sanatorio del Sur S.A.
Coordinator of this site? Confirm its status
San Miguel de TucumánArgentinaRecruiting
L2IP - Instituto de Pesquisas Clínicas Ltda
Coordinator of this site? Confirm its status
BrasíliaBrazilRecruiting
Instituto de Neurologia de Curitiba - Hospital Ecoville
Coordinator of this site? Confirm its status
CuritibaBrazilRecruiting
Nucleo de Pesquisa Clinica do Rio Grande do Sul NPCR
Coordinator of this site? Confirm its status
Porto AlegreBrazilRecruiting
Centro de Pesquisas Clinicas - CPCLIN
Coordinator of this site? Confirm its status
São PauloBrazilRecruiting
Hospital Universitario de la Princesa
Coordinator of this site? Confirm its status
MadridSpainRecruiting
Hospital Universitario Ramón y Cajal
Coordinator of this site? Confirm its status
MadridSpainRecruiting
Hospital Universitario Virgen Macarena
Coordinator of this site? Confirm its status
SevilleSpainRecruiting
Neurociencias Estudios Clinicos S.C.
Coordinator of this site? Confirm its status
CuliacánMexicoRecruiting
Clinstile, S.A. de C.V.
Coordinator of this site? Confirm its status
Mexico CityMexicoRecruiting
Uniwersyteckie Centrum Kliniczne
Coordinator of this site? Confirm its status
GdanskPolandRecruiting
Uniwersytecki Szpital Kliniczny w Poznaniu
Coordinator of this site? Confirm its status
PoznanPolandRecruiting
Instytut Pomnik Centrum Zdrowia Dziecka
Coordinator of this site? Confirm its status
WarsawPolandRecruiting
Centro Clnico Acadmico - Braga, Associao (2CA-Braga)
Coordinator of this site? Confirm its status
BragaPortugalRecruiting
Unidade Local de Saúde de Coimbra, E.P.E.
Coordinator of this site? Confirm its status
CoimbraPortugalRecruiting
UH of State NPC Danulo Halytsky NMU in Lviv CID, Clinic of Neurology and Neurosurgery
Coordinator of this site? Confirm its status
LvivUkraineRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.